SCHEMBL30714593

SCHEMBL30714593

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NC3CN(C)CC3(F)F)c2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 3/20 0.32
MMP13 P45452 3/20 0.32
ACACB O00763 1/20 0.32
HPGD P15428 1/20 0.31
HTR3A P46098 1/20 0.31
MMP2 P08253 2/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
RAB9A P51151 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
ADAM17 P78536 1/20 0.30
MCHR1 Q99705 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714629 0.85 ADAM17 (0.36) MMP13HPGDHTR3AMMP2ADAM17
SCHEMBL26868529 0.85 DGAT2 (0.36) MMP13HPGDMMP2ADAM17
SCHEMBL30714707 0.85 HTR3A (0.44) MMP13HTR3AMEN1KMT2A
SCHEMBL30714614 0.84 GUCY1B2 (0.40) HTR3A
SCHEMBL30714662 0.84 CYP11B2 (0.33) MMP12MMP13HTR3AKMT2A
SCHEMBL31539873 0.83 SLC8A1 (0.34) ACACBHPGDHTR3AKDM4EMEN1
SCHEMBL30714585 0.83 SLC6A5 (0.42) HPGDHTR3AKDM4EALDH1A1
SCHEMBL24484973 0.82 LMNA (0.41) KDM4EMEN1ALDH1A1POLBMAPT
SCHEMBL30656031 0.82 ESR1 (0.32) MMP12MMP13ACACBKDM4EMEN1
SCHEMBL26695999 0.82 ADAM17 (0.35) MMP12MMP13HTR3AMMP2ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MMP12 1218/4885MMP13 1106/4885ACACB 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.